Evenity (Romosozumab) and Finasteride Interaction

Why This Combination Comes Up

Men with osteoporosis who also have androgenetic alopecia or benign prostatic hyperplasia (BPH) sometimes need both drugs at once. Romosozumab received FDA approval in April 2019 for osteoporosis in postmenopausal women at high fracture risk, and prescribing data show growing off-label use in men with severe bone loss [1]. Finasteride, approved for BPH at 5 mg and for male pattern hair loss at 1 mg, is one of the most prescribed 5-alpha reductase inhibitors (5-ARIs) worldwide [2]. Because both drugs interface with the androgen-bone axis through different entry points, clinicians understandably question whether concurrent use is safe.

The short answer: no known pharmacokinetic clash. The longer answer involves understanding how DHT contributes to bone anabolism and what happens when you suppress it during a 12-month romosozumab course.

Pharmacokinetic Profile: No Metabolic Overlap

Romosozumab is a humanized IgG2 monoclonal antibody. It does not pass through hepatic cytochrome P450 metabolism. Instead, like other therapeutic antibodies, it is cleared through target-mediated disposition and proteolytic catabolism in the reticuloendothelial system [3]. It has no affinity for P-glycoprotein or other efflux transporters.

Finasteride is a small molecule metabolized primarily by CYP3A4 in the liver, with minor contributions from CYP3A5 [4]. Its protein binding is approximately 90%, and it does not inhibit or induce CYP enzymes at therapeutic doses.

These two drugs occupy entirely different pharmacokinetic compartments. No competition for the same enzyme. No transporter conflict. No protein-binding displacement. From a strict drug-drug interaction standpoint, the combination is pharmacokinetically clean. Neither the romosozumab FDA label nor the finasteride FDA label lists the other drug as a contraindication or interaction [1][5].

The Pharmacodynamic Concern: Androgens and Bone Formation

The real question is pharmacodynamic. Testosterone and its more potent metabolite, dihydrotestosterone (DHT), both contribute to bone health in men. DHT acts on androgen receptors in osteoblasts and osteocytes to promote bone formation and inhibit apoptosis of bone-forming cells [6]. A 2008 study published in the Journal of Clinical Endocrinology & Metabolism (N=120 healthy men) demonstrated that DHT suppression via dutasteride (a dual 5-ARI, more potent than finasteride) did not significantly reduce bone mineral density over 3 years [6].

Finasteride selectively inhibits type II 5-alpha reductase, reducing serum DHT by approximately 70% at the 5 mg dose and roughly 65% at the 1 mg dose [5]. Type II predominates in the prostate and hair follicles. Type I, which finasteride does not block, operates in skin and liver. This selectivity means that some local DHT production in bone tissue (which expresses both isoforms) may be preserved during finasteride therapy.

Still, the theoretical concern remains: romosozumab works by inhibiting sclerostin, a protein that suppresses the Wnt signaling pathway in osteoblasts [1]. Wnt activation drives osteoblast differentiation and bone formation. If androgen receptor signaling in osteoblasts is simultaneously dampened by reduced DHT, the magnitude of romosozumab's anabolic response could be attenuated. No clinical trial has directly tested this hypothesis.

What the Clinical Evidence Actually Shows

No randomized controlled trial has studied romosozumab and finasteride together. The available evidence comes from parallel lines of research.

Romosozumab in men. The BRIDGE trial (N=245) randomized men with osteoporosis to romosozumab 210 mg SC monthly versus placebo for 12 months [7]. Lumbar spine BMD increased by 12.1% with romosozumab versus 1.2% with placebo. Total hip BMD rose by 2.5% versus −0.5%. The trial excluded men on 5-ARIs, so direct extrapolation is limited.

5-ARIs and bone density. A population-based cohort study using Danish national registries (N=48,365 men on 5-ARIs) found no increased fracture risk with finasteride or dutasteride use over a median follow-up of 4.2 years [8]. A smaller prospective study in the Journal of Bone and Mineral Research confirmed stable BMD during 5-ARI therapy over 3 years in eugonadal men [6].

Testosterone and sclerostin. A cross-sectional analysis published in Osteoporosis International (N=1,606 men, MrOS cohort) found that lower free testosterone was associated with higher sclerostin levels [9]. This suggests that adequate androgen signaling may keep sclerostin lower at baseline, and that androgen suppression might raise sclerostin, partially counteracting romosozumab's mechanism. Finasteride does not lower testosterone (it actually raises serum testosterone modestly by blocking its conversion to DHT), so this concern is less pronounced than it would be with androgen deprivation therapy.

The net interpretation: finasteride is unlikely to meaningfully impair romosozumab's bone-building effect, but prospective data confirming this are absent.

Cardiovascular Risk: An Independent Concern for Romosozumab

The ARCH trial (N=4,093 postmenopausal women) compared romosozumab followed by alendronate versus alendronate alone [10]. The romosozumab arm showed a higher rate of adjudicated cardiovascular serious adverse events: 50 events (2.5%) versus 38 events (1.9%) in year one. This finding led the FDA to add a boxed warning advising against use in patients who have had a myocardial infarction or stroke within the preceding year [1].

Finasteride does not carry cardiovascular risk signals at approved doses. A 2019 meta-analysis in JAMA Dermatology found no significant association between finasteride 1 mg and cardiovascular events [11]. The two drugs do not compound each other's cardiac risk profile, but any patient starting romosozumab should undergo cardiovascular risk assessment regardless of concomitant medications.

Monitoring Protocol for Concurrent Use

Because no formal interaction study exists, the monitoring approach should be conservative. The following protocol is based on the individual FDA labels and expert consensus from the Endocrine Society's male osteoporosis guidelines [12].

Before starting romosozumab:

• DXA scan (lumbar spine, total hip, femoral neck)
• Serum total testosterone and free testosterone
• Bone turnover markers: P1NP (formation) and CTX (resorption)
• 25-hydroxyvitamin D level (target ≥30 ng/mL)
• Basic metabolic panel including calcium
• Cardiovascular risk assessment (10-year ASCVD risk)

During the 12-month romosozumab course:

• P1NP and CTX at months 3 and 6 to confirm anabolic response
• Serum calcium at month 1 (hypocalcemia risk, particularly in patients with renal impairment)
• Repeat DXA at month 12 to assess treatment effect
• Monitor for injection-site reactions, arthralgia, and headache (the most common adverse events per the label)

Finasteride-specific monitoring:

• PSA at baseline and annually (finasteride reduces PSA by approximately 50%; any confirmed PSA rise on therapy warrants urologic evaluation)
• Watch for sexual side effects: decreased libido, erectile dysfunction, and ejaculatory disorders occur in 3.4% to 15.8% of men on finasteride per the FDA label [5]

If P1NP fails to rise by at least 50% from baseline by month 3, clinicians should evaluate whether the romosozumab response is suboptimal and investigate causes. Low testosterone, vitamin D deficiency, or chronic glucocorticoid use would each warrant independent correction.

Dose Adjustment: Not Required

Neither drug requires dose modification when used with the other. Romosozumab is administered as 210 mg (two 105 mg subcutaneous injections) monthly for 12 doses. This is a fixed dose with no renal or hepatic adjustment in the current label [1]. Finasteride is given at 1 mg daily for hair loss or 5 mg daily for BPH, also without dose modification based on comedications [5].

There is no pharmacologic rationale for reducing either dose. Monoclonal antibodies do not compete with small molecules for clearance pathways. The 12-month romosozumab course is already time-limited by design because sclerostin antibody responses plateau and bone formation markers return toward baseline after approximately 9 to 12 months of treatment.

Transitioning After Romosozumab

After completing 12 months of romosozumab, patients must transition to an antiresorptive agent. The FDA label and the FRAME extension study data show that BMD gains are rapidly lost without sequential antiresorptive therapy [13]. Alendronate or denosumab are the standard follow-on agents.

Finasteride can continue without interruption through this transition. Neither alendronate nor denosumab has pharmacokinetic interactions with finasteride. For men on both romosozumab and finasteride, the transition timeline should follow standard osteoporosis sequencing: begin oral alendronate (70 mg weekly) or denosumab (60 mg SC every 6 months) within one month of the final romosozumab injection.

One important caveat for the denosumab pathway: discontinuation of denosumab after any duration of use triggers rapid bone loss and rebound vertebral fractures [14]. This is an independent risk unrelated to finasteride but must be discussed at the time of sequencing.

Special Populations

Men on androgen deprivation therapy (ADT). ADT for prostate cancer suppresses both testosterone and DHT far more aggressively than finasteride does. The pharmacodynamic concern about impaired anabolic bone response is more clinically relevant in this population. Romosozumab has not been studied in men on ADT. These patients should be managed by a multidisciplinary team including oncology, endocrinology, and urology.

Hypogonadal men. Men with baseline total testosterone below 300 ng/dL who are also on finasteride represent a group where androgen support for bone is already compromised. Consider testosterone replacement therapy (TRT) before or alongside romosozumab in these patients, per the Endocrine Society's hypogonadism guidelines [15]. Finasteride is sometimes co-prescribed with TRT to prevent DHT-mediated hair loss, a rational approach that does not eliminate the bone-protective effect of restored testosterone.

Older men with BPH. Men over 65 on finasteride 5 mg for BPH who develop osteoporosis are the most common clinical scenario for this combination. Age-related decline in testosterone, combined with DHT suppression, creates a milieu where bone anabolic therapies may be most needed. Romosozumab's bone-forming mechanism works independently of androgen signaling through the Wnt pathway, so even in the setting of reduced DHT, the primary drug effect should be preserved.

Patient Counseling Points

Patients should understand three things. First, no evidence suggests that finasteride blocks or weakens romosozumab. Second, romosozumab is a 12-month course with a defined endpoint, not a lifelong therapy. Third, the cardiovascular boxed warning on romosozumab applies regardless of other medications.

Patients should report new chest pain, sudden weakness, slurred speech, or severe headache immediately during romosozumab treatment. They should also report jaw pain or thigh pain (rare signals of osteonecrosis of the jaw or atypical femoral fracture, though these are more commonly associated with prolonged antiresorptive use rather than short-course anabolic therapy).

Men taking finasteride 1 mg for hair loss should be told that stopping finasteride during the romosozumab course is not medically necessary and that hair loss will resume within 3 to 6 months of discontinuation.